null

Anti-Human CD279 (PD-1) (Nivolumab) - Dylight® 488 Biosimilar (IVMB0437)

SKU:
IVMB0437
Antibody Type:
Dylight Biosimilar
Applications:
IHC
FC
Drug Development
Inflammatory Response Assays
Pharmacokinetics
Disease Area:
Cancer Immunotherapy
Disease Area:
Autoimmune Diseases
€749

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human CD279 (PD-1) (Nivolumab) - Dylight 488
SKU:IVMB0437
Size:100 µg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:5C4.B8
Target:PD-1
Isotype:Human IgG1κ
Host Species:Human
Reactivity:Human/Cynomolgus Monkey
Applications:FA
Expression Host:HEK-293 Cells
FC Effector Activity:Active
Synonyms:PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1
Product Concentration:0.2 mg/ml
Excitation Laser:Blue Laser (493 nm)
Immunogen:Human PD-1
Applications and Recommended Usage:FC The suggested concentration for Nivolumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Antigen Distribution:PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Formulation:This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Nivolumab. Clone 5C4.B8 binds to the extracellular portion of Human/Cynomolgus PD-1 and does not bind to other IgG superfamily proteins. This product is for research use only.
Additional Applications Reported In Literature:IHCFA
Additional Reported Applications For Relevant Conjugates:B

Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.

Ligand/Receptor:PD-L1 and PD-L2
Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Storage and Handling:This DyLight 488 conjugate is stable when stored at 2-8°C.Do not freeze.
Research Area:Biosimilars

Related Products